Osteoarthritis management of the knee--treatment options post the NSAID cardiotoxicity controversy.
This series of articles facilitated by the Cochrane Musculoskeletal Group (CMSG) aims to place the findings of recent Cochrane musculoskeletal reviews in a context immediately relevant to general practitioners. This article considers treatment options for osteoarthritis management of the knee post the 'NSAID cardiotoxicity controversy'.
Gartlan
Jan
J
Menzies Research Institute, University of Tasmania, Australia. janette.gartlan@utas.edu.au
Nelson
Mark
M
Jones
Graeme
G
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions; D005194:Family Practice / Q000379:methods; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use; D007270:Injections, Intra-Articular; D007717:Knee / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000503:physiopathology; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D006820:Hyaluronic Acid